Skip to main content
Caplight Logo









iBody Inc.

iBody Inc.

Private
NagoyaHealthcare & Life Scienceshttps://www.ibody.co.jp/

Last Round

Strategic

Jan 5, 2023

Est. Valuation

$8.08M

Total Funding Raised

$3.21M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

iBody Inc. is a biotechnology company that provides a monoclonal antibody discovery platform and contract research services for pharmaceutical and diagnostic applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

antibody discoverymonoclonal antibody generationcontract research organizationCROcustom antibody servicedifficult antibody targetstherapeutic antibody discoveryEcobody technologyhuman monoclonal antibodiesrabbit monoclonal antibodiessingle-cell antibody discoveryantibody out-licensingcell-free expressionpharma servicesdiagnostic development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

iBody Inc. Comparables

Compare iBody Inc. with similar companies based on industry and business-model similarity.

iBody Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Epsilon Molecular Engineering, Inc.
85%
株式会社イーベック
80%
MabGenesis株式会社
78%

iBody Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicJan 5, 2023
VC RoundAug 3, 2020
SeedMay 16, 2018

Key People

Founding team and executive leadership

Yo Amakusa

CEO

Executive Team

iBody Inc. Investors

Notable investors and investment history

iBody Inc. investors
InvestorRounds
OKB CapitalVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 26, 2026

    Monthly visitors increased 80% MoM.

  • Mar 3, 2026

    Monthly visitors increased 37% MoM, reaching 2.1K.

Recent news

Latest coverage and updates

  • integrates_withJul 30, 2026

    iBody Inc integrated with NovAliX SAS on Jul 30th '26.

iBody Inc. Filings

Explore SEC and related filing metadata, where available.

iBody Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about iBody Inc.'s valuation, stock price, and market status.

Is iBody Inc. a public or private company?

iBody Inc. is a private company.

What is the current stock price of iBody Inc.?

iBody Inc. is a private company, so its shares have no public market price. Caplight tracks iBody Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is iBody Inc. worth (valuation)?

iBody Inc.'s valuation is estimated at $8.1M based on funding round data.

Can I buy iBody Inc. stock?

iBody Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was iBody Inc.'s last funding round?

iBody Inc.'s most recent funding round was Strategic on January 5, 2023.

Who are the main investors in iBody Inc.?

Key investors in iBody Inc. include OKB Capital.

Will iBody Inc. IPO soon?

No public IPO plans have been announced for iBody Inc..

How can I track iBody Inc. secondary market activity?

Caplight tracks bids, offers, and trades in iBody Inc.'s shares on secondary markets.

Firmographic Details

HeadquartersNagoya
Employee Range7
Year Founded2018
Last FundingJan 5, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?